SOURCE: Ingen Technologies Inc.

Ingen Technologies Inc.

May 30, 2012 08:15 ET

Ingen Technologies Begins Execution of Reorganizational Plan

RIVERSIDE, CA--(Marketwire - May 30, 2012) - Ingen Technologies, Inc. (PINKSHEETS: IGNT) announced today that it has agreed to execute a Plan of Reorganization that would include reductions in debt and liabilities, various merger/acquisition proposals, new medical product distribution programs and finally, moving the company from the OTC Pinksheets to a fully reporting company listed on the OTC Markets QX exchange.

Ingen is current with its reporting obligations under the OTC Markets. The quarter ending February 29, 2012 was recently filed and is available on the OTC Markets website. The company hopes to have the Annual Report filed by July 15th, 2012.

Gary B. Tilden, COO of Ingen Technologies, stated, "The company is currently in discussions with several other companies regarding a merger/acquisition as a part of the Plan of Reorganization. Furthermore, management is now working on increasing sales through new distribution channels. Our Oxyview product line continues to have solid sales in certain sectors of the growing respiratory markets and we believe has the potential for major growth during the next 12 months. The company is evaluating its options with potential new products for possible cross-marketing with the end result being to maximize every sales dollar."

For more updated information on Ingen Technologies please go to the following link:

About Ingen:
Ingen Technologies is a Georgia Corporation, and a holding company that wholly owns a subsidiary doing business as a Nevada Corporation. The subsidiary is a Medical Device Manufacturer licensed in California with the Department of Public Health. The subsidiary manufactures proprietary medical products for the respiratory industry. The company owns issued patents, trademarks and other intellectual property securing the rights to their products. These respiratory products are distributed worldwide. These products are registered with the Food & Drug Administration as Class-I devices.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Contact Information